Corteria Pharmaceuticals, a Paris-based biopharmaceutical company, has raised €65 million in Series A funding to advance its pipeline of therapies for heart failure subpopulations. The round was led by OrbiMed and Jeito Capital, with participation from existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.
As a result of the funding, Erez Chimovits from OrbiMed and Andreas Wallnoefer from Jeito Capital will join the company's board of directors. Corteria was founded in 2021 by Philip Janiak and Marie-Laure Ozoux. The company's mission is to develop first-in-class therapies that address the unmet needs of patients with heart failure. Its pipeline includes three drugs that are highly differentiated from existing therapies:
